Trial Profile
A Multicenter Randomized Study Evaluating Dosing Regimens for Treatment With Intravitreal Ranibizumab Injections in Subjects With Macular Edema Following Retinal Vein Occlusion
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 08 May 2023
Price :
$35
*
At a glance
- Drugs Ranibizumab (Primary)
- Indications Diabetic macular oedema; Retinal vein occlusion
- Focus Therapeutic Use
- Acronyms SHORE
- Sponsors Genentech
- 01 May 2023 Results of post hoc analysis (n=95) assessing the spectral-domain optical coherence tomography (SD-OCT) biomarkers associated with ranibizumab injection frequency after 7 monthly doses for macular edema due to retinal vein occlusion, published in the American Journal of Ophthalmology.
- 30 Sep 2015 New trial record